BioNTech's ASCO Data and $1 Billion Buyback Show Pivot Progress, But Market Remains Unimpressed

BioNTech unveils strong Phase 2 results for pumitamig in NSCLC at ASCO, announces $1B buyback and cost cuts, but stock remains below analyst price targets.

BioNTech returned from this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago armed with fresh data on two late-stage oncology candidates, yet the stock continues to trade well below the levels analysts consider fair value. The disconnect between clinical momentum and market sentiment was impossible to ignore as the company also confirmed plans for a $1 billion share buyback and a deeper cost-cutting drive — moves designed to shore up confidence while investors wait for the ultimate Phase 3 verdict.

The centerpiece of BioNTech’s ASCO presentation was pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, developed in collaboration with Bristol Myers Squibb. On May 30, the partners disclosed interim results from the Phase 2 ROSETTA Lung-02 study, which is testing pumitamig plus chemotherapy in previously untreated, advanced non-small cell lung cancer (NSCLC). The data showed a 100% disease control rate across the full evaluable cohort. Among patients with a tumor proportion score of 50% or higher, the confirmed objective response rate hit 100%. In histology subgroups, non-squamous patients posted a 57.1% response rate and squamous patients 68.4%. Those figures mark the third global dataset in which pumitamig combined with chemo has demonstrated consistent antitumor activity — exactly the kind of repeatability BioNTech needs to validate its oncology pivot.

Safety data from the 9.0-month median follow-up offered a mixed picture. Grade 3 or higher adverse events occurred in 48.8% of patients, with 23.3% attributed specifically to pumitamig. Treatment discontinuation due to side effects stood at 9.3%. While manageable, the safety profile will face closer scrutiny as the program moves into registration-directed studies.

BioNTech also presented an update on gotistobart, its anti-CTLA-4 candidate designed to selectively deplete regulatory T cells in the tumor microenvironment. Phase 2 data from the PRESERVE-004 trial in heavily pretreated patients with platinum-resistant ovarian cancer showed sustained antitumor activity and clinically relevant survival signals, bolstering the case for a chemotherapy-free option in a difficult-to-treat population.

The broader oncology pipeline now includes more than 25 Phase 2 and Phase 3 trials, 13 of which are registration-enabling. On the corporate side, the company has already launched seven separate Phase 3 studies for pumitamig, including ROSETTA Lung-02, -201, and -202, which pit the candidate directly against pembrolizumab, the current standard of care in NSCLC.

Wall Street analysts are split on what all this means for the stock. UBS upgraded BioNTech to Buy and lifted its price target from $117 to $135, with analyst David Dai arguing that the market is too pessimistic. He highlighted pumitamig’s strong, repeatable lung cancer data and noted potential expansion into triple-negative breast and colorectal cancers. Jefferies, which maintained its Buy rating, saw the stock slip 3.9% on June 1 but held firm. On the cautious side, Bernstein initiated coverage at Market Perform with a $96 target, signaling limited upside from current levels. The consensus among 19 analysts sits at $129.56, with a range spanning $94 to $158 — a spread that underscores the deep uncertainty about how much oncology revenue the company can eventually generate.

BioNTech’s financial picture remains a study in contrasts. First-quarter revenue fell to €118.1 million from €182.8 million a year earlier, as COVID-19 vaccine sales continue to decline. The net loss widened to €531.9 million, or €2.10 per share, compared with €1.73 per share in the year-ago period. That red ink is the price of restructuring the business around oncology. The company’s cash buffer, however, remains formidable: €16.8 billion in cash, cash equivalents, and securities at the end of March.

Management is now moving to make that cushion last. BioNTech plans to exit sites in Idar-Oberstein, Marburg, Singapore, and several CureVac locations, affecting up to 1,860 jobs. The annual savings from the restructuring are expected to reach approximately €500 million by 2029. For 2026, the company reiterated its guidance: revenue of €2.0 to €2.3 billion, adjusted R&D spending of €2.2 to €2.5 billion, and selling and administrative costs of €700 to €800 million.

On the shareholder front, BioNTech has authorized a share buyback of up to $1 billion, representing roughly 4.2% of outstanding shares. Institutional investors have been quietly building new positions, even as the stock hovers around €78.40 — about 23% below its 52-week high of €101.90 and barely 8% above the year’s low from March. Year-to-date, the stock is down nearly 5%, and on a 12-month basis it has lost 20.88%.

Adding to the strategic shuffle, co-founders Prof. Ugur Sahin and Prof. Özlem Türeci are moving ahead with plans to establish an independent company focused on next-generation mRNA innovations. BioNTech would contribute certain rights and technologies in exchange for a minority stake. A binding agreement is expected by the end of the first half of 2026, with the founders transitioning to the new entity by year-end. The move sharpens BioNTech’s corporate structure but also raises questions about leadership going forward.

The next major catalyst remains the Phase 3 program for pumitamig. If the ROSETTA studies confirm the signals seen so far, BioNTech’s oncology narrative will gain substantial credibility. Until those results materialize, expected in the second half of the decade, the stock will continue to straddle two worlds — backed by a €16.8 billion war chest and a promising pipeline, yet burdened by widening losses and a market that wants to see proof in Phase 3 before paying up for the pivot.